A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma

L. Rothenberg, Mace; V. Cox, John; F. DeVore, Russell; D. Hainsworth, John; Pazdur, Richard; E. Rivkin, Saul; S. Macdonald, John; E. Geyer, Charles; F. Sandbach, John; L. Wolf, Daniel; Scott Mohrland, J.; Elfring, Gary; L. Miller, Langdon; D. Von Hoff, Daniel

doi:10.1002/(sici)1097-0142(19990215)85:4<786::aid-cncr5>3.0.co;2-9

Public

A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma

Shared by NobleBlocks on Feb 15, 1999 • 12:00 AM UTC

Authors:

Mace L. Rothenberg

John V. Cox

Russell F. DeVore

Abstract

CPT-11 can induce tumor regression in patients with metastatic colorectal carcinoma that has progressed during or shortly after 5-FU-based chemotherapy. Gastrointestinal events and neutropenia were the most common serious toxicities. Given the trend toward a higher response rate without substantiall...

Subject

Medicine

Irinotecan

Toxicity

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!